(Total Views: 717)
Posted On: 08/26/2020 7:26:57 AM
Post# of 154003
Quote:
Announced today the Company has reached the requisite number of enrolled patients in its Phase 3 trial for COVID-19 patients with severe-to-critical symptoms to perform an interim analysis following the 28-day phase of the trial.
This is good news for sure. Enrollment in CD12 has picked up speed. I wonder if this is the U.K. contributing already ....
In any case, the signal is that we should continue and accelerate enrollment so that, by the time we do our interim, we will be well into our final 390 target.
No slow down in enrollment just incase we need to go the distance, by the contrary, keep it up !!!
(5)
(0)
